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Aim: The automated Cepheid GeneXpert system provides rapid PCR results and can be used for the identification of VRE. We aimed
to evaluate the use of the Cepheid Xpert vanA/vanB real-time PCR assay for the detection of VRE from rectal swabs of patients newly
admitted to intensive care units in a hospital setting.
Materials and methods: Rectal swab samples of patients newly admitted to 6 intensive care units from March 2011 to February 2012
were obtained. The specimens were analyzed by the GeneXpert system. The results were reported for both vanA and vanB as negative
or positive.
Results: Comparing the number of inpatients, most of the samples were delivered from the neurosurgery (48.3%), pediatrics (33.3%),
and neonatology (20.6%) intensive care units. The positive samples according to GeneXpert vanA/vanB method were 33 (7.3%) among
454 rectal samples. Of these positive samples 22 (4.9%) were vanA, 10 (2.2%) were vanB, and 1 sample (0.2%) was vanA and vanBharboring, by PCR.
Conclusion: As a rapid, easy to use, and labor-saving method GeneXpert vanA/vanB can detect VRE-positive patients, particularly in
risk groups, as soon as they are admitted to hospital so that infection control policies can be applied immediately.
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1. Introduction
Enterococci are one of the leading causes of nosocomial
infections. In recent years enterococci have become
increasingly resistant to a wide range of antimicrobial agents.
In addition, vancomycin-resistant enterococci (VRE) have
become resistant to glycopeptide antibiotics. Glycopeptideresistant enterococci have become a main hazard to
hospitalized patients. Similar to methicillin-resistant
Staphylococcus aureus, VRE can give rise to significant
nosocomial epidemics and can raise morbidity, mortality,
and costs related to admission to the hospital (1,2).
Patients monitored in a medical intensive care unit
(ICU) have a high risk of VRE colonization/infection, and
active VRE surveillance of high-risk group patients is crucial
for early detection and implementation of precautions to
impede the development of infection and the spread of VRE
(3,4).
Rapid and accurate microbiologic identification of VRE is
essential for the management of both colonized and infected
patients in order to select adequate treatment and to
prevent the spread of VRE by implementing proper barrier
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precautions. VRE are classically screened by culture-based
processes, considered the “gold standard,” which are time
consuming (48–72 h), and other phenotypic investigations
are needed. Nucleic acid amplification tests can be used
for the detection of VRE, but complicated extraction and
detection steps are required (5–7). Moreover, a culture
step from a selective enrichment broth or solid media may
be needed for some methods (8,9). Recently, automated
real-time PCR in vitro test assays for the rapid detection
of vancomycin resistance, directly from perianal or rectal
swabs, came into use (10,11). The GeneXpert system
(Cepheid, Sunnyvale, CA, USA) merges automated nucleic
acid sample preparation, amplification, and real-time
detection of enterococcus DNA in a disposable, macro/
microfluidic cartridge using the GeneXpert Dx system
instrument and generally provides results in less than 1 h
(12).
The aim of this study was to evaluate the use of the
Cepheid Xpert vanA/vanB real-time PCR assay for the
detection of VRE from rectal swabs of patients newly
admitted to ICUs in a hospital setting.
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2. Materials and methods
Patients newly admitted to ICUs from March 2011 to
February 2012 were included in the study. Routine
surveillance by culture method was also carried out on
all the patients. The 6 different ICUs involved in the study
were anesthesiology and reanimation, neurology, internal
medicine, neurosurgery, pediatrics, and neonatology.
Rectal swab samples were collected from each patient
using Amies transport medium (Meus, Italy) and
transported to the laboratory. The samples were analyzed
by automated multiplex real-time PCR assay (GeneXpert
vanA/vanB, Cepheid, Sunnyvale, CA, USA) according to
the recommendations of the manufacturer. Briefly, the
swab sample obtained from the patient was added to the
elution buffer and vortexed for 1 min. The buffer with the
swab was transferred to a single-use disposable cartridge
containing integrated chambers and reagents. Then the
cartridge was placed in the GeneXpert™ Dx module and
run. The results were reported for both vanA and vanB
as negative or positive. When only vanB was positive, the
culture method was used as a confirmatory test.
3. Results
Over a period of 11 months rectal swab samples from
454 patients were obtained, and VRE colonization was
evaluated. Comparing the number of inpatients, most
of the samples were delivered from the neurosurgery
(48.3%), pediatrics (33.3%), and neonatology (20.6%)
ICUs, respectively. However, samples that showed the
presence of VRE by multiplex real-time PCR were low

(6.9%, 5.3%, and 2.8%, respectively). Although the number
of delivered samples was low (7.3%) compared to the total
number of inpatients in the anesthesiology and reanimation
ICUs, VRE by PCR was detected in 36% of the samples.
Furthermore, multiplex real-time PCR detected 22 (4.9%)
samples that showed only vanA- harboring VRE, 10 (2.2%)
with only vanB-harboring VRE, and 1 sample (0.2%) with
both vanA and vanB-harboring VRE (Table). Therefore, the
presence of vanB was seen in 11 samples (2.4%) in total.
Five of the patients harboring vanB only were negative
by the culture method, and the remaining 5 could not be
evaluated by culture because they died or were referred to
another hospital.
4. Discussion
The Gene Xpert vanA/vanB assay was recently described
as a rapid and accurate method for detecting VRE from
perianal/rectal swabs of colonized or infected patients.
This fully automated process combines DNA extraction,
real-time PCR amplification, and detection steps, and the
results are obtained generally in less than 1 h (10,12,13).
In the first report using the assay for detecting VRE the
sensitivity and negative predictive value of the method were
100% compared to enriched culture, and it was indicated
that this method could be used to control only positive PCR
results in order to reduce laboratory labor (12). This assay
has a higher sensitivity for the detection of both vanA and
vanB-harboring VRE at lower bacterial loads (10–100 cfu/
mL) and could also provide rapid detection of VRE carriage
in patients at the time of hospital admission in conjunction

Table. Vancomycin-resistant enterococci (VRE) positive results of samples obtained from 6 different
intensive care units (ICUs) by Cepheid Xpert vanA/vanB assay.
VRE positive

Number of
inpatients

Obtained samples
n (%)

AR-ICU

336

25 (7.4)

VanA positive VanB positive Total
n
n
n (%)
7
2
9 (36)

NEU-ICU

324

32 (9.9)

1

1

2 (6.3)

IM-ICU

647

56 (8.7)

3

1

4 (7.1)

NC-ICU

362

175 (48.3)

7

5

11 (6.3)

P-ICU

285

95 (33.3)

3

2

5 (5.3)

NE-ICU

344

71 (20.6)

2

-

2 (2.8)

TOTAL

2298

454 (19.7)

23

11

33 (7.3)

VRE: vancomycin-resistant enterococci
AR-ICU: Anesthesiology and Reanimation Intensive Care Unit
NEU-ICU: Neurology Intensive Care Unit
IM-ICU: Internal Medicine Intensive Care Unit
NC-ICU: Neurochirurgie Intensive Care Unit
P-ICU: Pediatrics Intensive Care Unit
NE-ICU: Neonatology Intensive Care Unit
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with culture confirmation (14). Therefore, we chose this
method to detect VRE-positive patients as soon as they were
admitted to ICUs in our hospital in order to apply infection
control policies immediately. Patients with a positive result
for VRE are reported to infection control nurses.
In the study period we collected specimens from 454
(19.8%) patients among 2298 total ICU inpatients (Table).
Most of the samples were obtained from the neurosurgery
ICU; this may be because these patients stay for a short
period of time after surgery and so patient turnover was
high compared to other ICUs. We requested rectal swab
samples from all patients who were newly admitted to the
ICUs; however, some of the units sent only a small portion
of all samples. In particular, the proportion of specimens
obtained from the anesthesiology and reanimation,
neurology, and internal medicine ICUs were lower when
compared to the number of inpatients (7.3%, 9.9%, and
8.7%, respectively) (Table). Continuing routine weekly
surveillance by culture method may be one of the reasons
for this. The intensive care staff may have been reluctant to
send extra samples, because this type of specimen collection
can be offensive. Informing the intensive care staff about
the importance of early detection of VRE could increase the
sample sending rate.
The prevalence of VRE carriage on ICU admission has
been reported between 1.4% and 25% in different studies
(12,15–20). The number of positive samples by GeneXpert
vanA/vanB method was 33 (7.3%) among the 454 rectal
specimens sent in our study. Some of the risk factors for
VRE carriage are antibiotic use and hospitalization (20–
22). The positivity rate was rather high in samples from
anesthesiology and reanimation ICU (36%). The patients in
this unit have been given extensive antibiotics and had the
most severe status and hospitalization history. Therefore,
these patients’ characteristics may be the reason for the
high rate of VRE positivity. Conversely, the patients in
neonatology ICU have a lower rate of antibiotic use and a
shorter hospitalization history. These conditions may result
in the low VRE positivity.
One limitation of this study was that all vanB-positive
patients were not compared with culture method, due to
reasons beyond our control. The Gene Xpert vanA/vanB
assay has improved sensitivity compared to direct cultures;

therefore, labor-intensive broth-enrichment is not required
(10). However, the results of GeneXpert vanA/vanB have
a very low PPV and should be confirmed by culture,
especially the vanB gene (23). The possible explanations for
the false-positive reactions for vanB were lack of specificity
of primers/probes of the PCR assay or the presence of van
genes in uncultured bacteria (12). Furthermore, when
stool is present on rectal swabs, it may carry risk of vanB
detection from aerobic and anaerobic bacteria of stool flora
and contain PCR inhibitors (24). To avoid inhibition of
amplification, samples need to be prepared carefully (13).
The Gene Xpert vanA/vanB system gives an error message
when stool is present on rectal swabs. When we saw this
message during the process, we diluted the swab and repeated
the test. Despite this, we have discrepant results between
PCR and culture. Studies issuing false-positive results due
to vanB suggest that follow-up culture be performed on any
vanB-positive results (11,25,26). If the presence of vanB is
low in the setting, culture backup may not be warranted. To
assess the utility of culture confirmation for vanB, studies
are ongoing (10). The presence of vanB was also low in
our study group (2.4%), and so confirming vanB-positive
samples by culture method may not be necessary.
There are few reports from Turkey detailing Cepheid
Xpert vanA/vanB system use in the subsequent evaluation of
VRE epidemics and sporadic cases (27,28). In other reports
the Cepheid Xpert vanA/vanB method was evaluated for
detecting VRE from rectal specimens. The results of the
Cepheid Xpert vanA/vanB method have been compared
to conventional culture methods in these studies (29,30).
However, the administration of this system in samples of
patients newly admitted to ICU had not been reported.
To our knowledge this is the first report on the use of the
Cepheid Xpert vanA/vanB in patients newly admitted to
ICUs for detecting VRE from rectal specimens in Turkey.
When total costs including savings from a potential
decrease in infections, ease of use, and laboratory labor
savings are considered, the assay’s relative cost-effectiveness
can be estimated truly (10). Therefore, this rapid, easy to
use, and labor-saving method can be used to detect VREpositive patients in risk groups as soon as they are admitted
to hospital in order to apply infection control policies
immediately.
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